Their findings aligned with previous studies, indicating no association between SGLT2 inhibitors and VTE risk (HR 1.39, 95% CI 0.32–5.94) compared with GLP-1 receptor agonists in T2DM patients, but a lower VTE risk was observed compared with DPP-4 inhibitors (HR 0.70, 95% CI 0.59–0.84). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.